



Paris, June 24th, 2010 - 5.45 pm

## AB Science has concluded a liquidity contract

**AB Science (ISIN: FR0010557264 – Ticker: AB) has concluded a liquidity contract with Société Générale Securities.**

As of June 23, 2010 and for a period ending at December 31, 2010, renewable by tacit agreement, AB Science has given the responsibility of the market stimulation of its shares under the AMAFI charter to Société Générale Securities through a liquidity contract.

The liquidity contract is then composed of:

- 100 000 euros.

### **About AB Science**

*Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. Masitinib, a lead compound, has already been registered in veterinary medicine in Europe and is pursuing three on-going phases 3 in human medicine in pancreatic cancer, GIST and mastocytosis.*

*AB Science is listed on NYSE Euronext Paris (Compartment B) - ISIN: FR0010557264 – Ticker: AB*



*Further information is available on AB Science's website: [www.ab-science.com](http://www.ab-science.com)*

### **Financial Communication & Press Relations**

**Citigate  
Dewe Rogerson**

Contacts Citigate Dewe Rogerson :  
Agnès Villeret - Tel: +33 1 53 32 78 95 - [agnes.villeret@citigate.fr](mailto:agnes.villeret@citigate.fr)